These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23209624)

  • 21. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.
    Ambrose CS; Yi T; Falloon J
    Influenza Other Respir Viruses; 2011 Nov; 5(6):389-97. PubMed ID: 21668683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
    Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
    Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.
    Toback SL; Ambrose CS; Eaton A; Hansen J; Aukes L; Lewis N; Wu X; Baxter R
    Vaccine; 2013 Apr; 31(14):1812-8. PubMed ID: 23395734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.
    Ambrose CS; Levin MJ; Belshe RB
    Influenza Other Respir Viruses; 2011 Mar; 5(2):67-75. PubMed ID: 21306569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.
    He XS; Holmes TH; Zhang C; Mahmood K; Kemble GW; Lewis DB; Dekker CL; Greenberg HB; Arvin AM
    J Virol; 2006 Dec; 80(23):11756-66. PubMed ID: 16971435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system.
    Luo C; Jiang Y; Du J; Tong J; Huang J; Lo Re V; Ellenberg SS; Poland GA; Tao C; Chen Y
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):602-609. PubMed ID: 33533072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(20):3053-60. PubMed ID: 22425787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Sun P; Crum-Cianflone NF; Defang G; Williams M; Ganesan A; Agan BK; Lalani T; Whitman T; Brandt C; Burgess TH
    Vaccine; 2017 Oct; 35(45):6103-6111. PubMed ID: 28987439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines.
    Ramakrishnan A; Althoff KN; Lopez JA; Coles CL; Bream JH
    Cytokine; 2012 Dec; 60(3):661-6. PubMed ID: 22989940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.
    Ambrose CS; Dubovsky F; Yi T; Belshe RB; Ashkenazi S
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2549-57. PubMed ID: 22410646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
    Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
    Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.
    Daley MF; Clarke CL; Glanz JM; Xu S; Hambidge SJ; Donahue JG; Nordin JD; Klein NP; Jacobsen SJ; Naleway AL; Jackson ML; Lee G; Duffy J; Weintraub E
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):59-68. PubMed ID: 29148124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
    Martin D; Menschik D; Bryant-Genevier M; Ball R
    Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N; Ghaffari G; Craig ET; Craig TJ
    Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J; He Y
    Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.